Drug Profile
Research programme: GRP78 inhibitors - Cancer Research Technology/The Institute of Cancer Research/Nuevolution
Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Cancer Research Technology; Nuevolution; The Institute of Cancer Research
- Developer Cancer Research Technology; Nuevolution
- Class Small molecules
- Mechanism of Action Molecular chaperone GRP78 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for research development in Cancer in Denmark
- 28 Feb 2023 No recent reports of development identified for research development in Cancer in United Kingdom
- 30 Jul 2019 Nuevolution has been acquired by Amgen